Intas Pharmaceuticals Limited — Clopidogrel Exporter Profile
Indian Pharmaceutical Exporter · #14 for Clopidogrel · $5.3M export value · DGFT Verified
Intas Pharmaceuticals Limited is the #14 Indian exporter of Clopidogrel with $5.3M in export value and 301 verified shipments. Intas Pharmaceuticals Limited holds a 2.1% market share in Clopidogrel exports across 19 countries. The company exports 75 pharmaceutical products worth $372.3M across 19 therapeutic categories.
Intas Pharmaceuticals Limited — Clopidogrel Export Profile: Buyers & Destinations
Where Does Intas Pharmaceuticals Limited Export Clopidogrel?
| Country | Value | Shipments | Share |
|---|---|---|---|
| AUSTRALIA | $2.2M | 62 | 51.2% |
| NETHERLANDS | $785.8K | 66 | 18.5% |
| BRAZIL | $526.7K | 20 | 12.4% |
| UNITED KINGDOM | $245.7K | 21 | 5.8% |
| SOUTH AFRICA | $140.6K | 7 | 3.3% |
| GREECE | $109.5K | 10 | 2.6% |
| MALAYSIA | $72.2K | 3 | 1.7% |
| GUYANA | $50.0K | 1 | 1.2% |
| POLAND | $40.6K | 9 | 1.0% |
| CONGO | $38.9K | 7 | 0.9% |
Intas Pharmaceuticals Limited exports Clopidogrel to 20 countries. The largest destination is AUSTRALIA accounting for 51.2% of Intas Pharmaceuticals Limited's Clopidogrel shipments, followed by NETHERLANDS (18.5%) and BRAZIL (12.4%). These destinations reflect Intas Pharmaceuticals Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Clopidogrel from Intas Pharmaceuticals Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| SANDOZ PTY LTD | AUSTRALIA | $908.2K | 27 |
| TO THE ORDER | HUNGARY | $642.4K | 52 |
| BROCACEF NL : HUB | NETHERLANDS | $466.1K | 39 |
| SANDOZ PTY LIMITED | AUSTRALIA | $463.6K | 13 |
| SANDOZ PTY LTD. | AUSTRALIA | $327.6K | 8 |
| ACCORD FARMACUTICA LTDA. | BRAZIL | $302.2K | 14 |
| ACCORD FARMACUTICA LIMITEDA | BRAZIL | $224.5K | 5 |
| ACCORD UK | UNITED KINGDOM | $158.1K | 13 |
| ALLOGA FRANCE | NETHERLANDS | $130.3K | 8 |
| ACCORD HEALTHCARE C/O UPD LEA GLEN | SOUTH AFRICA | $110.4K | 5 |
Intas Pharmaceuticals Limited supplies Clopidogrel to 33 buyers globally. The largest buyer is SANDOZ PTY LTD (AUSTRALIA), followed by TO THE ORDER (HUNGARY) and BROCACEF NL : HUB (NETHERLANDS). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Clopidogrel Export Value and How Much Does Intas Pharmaceuticals Limited Contribute?
India exported $133.2M worth of Clopidogrel through 6,037 shipments from 416 suppliers to 137 countries, serving 1,234 buyers globally. Intas Pharmaceuticals Limited contributes $5.3M to this total, accounting for 2.1% of India's Clopidogrel exports. Intas Pharmaceuticals Limited ships Clopidogrel to 20 countries through 33 buyers.
What Is the Average Shipment Value for Intas Pharmaceuticals Limited's Clopidogrel Exports?
Intas Pharmaceuticals Limited's average Clopidogrel shipment value is $17.6K per consignment, based on 301 shipments totaling $5.3M. The largest destination is AUSTRALIA (51.2% of Intas Pharmaceuticals Limited's Clopidogrel exports).
How Does Intas Pharmaceuticals Limited Compare to Other Indian Clopidogrel Exporters?
Intas Pharmaceuticals Limited ranks #14 among 416 Indian Clopidogrel exporters with a 2.1% market share. The top 3 exporters are AUROBINDO PHARMA LTD ($36.4M), ZENTIVA PRIVATE LIMITED ($19.0M), DR.REDDY'S LABORATORIES LTD ($14.3M). Intas Pharmaceuticals Limited processed 301 shipments to 19 destination countries.
What Clopidogrel Formulations Does Intas Pharmaceuticals Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PHARMA DRUGS & MEDI CLOPIDOGREL TABLETS | $345.2K | 9 |
| PHRM DRUG&MED:CLOPIDOGREL SANDOZ 75MG 2X | $328.8K | 7 |
| PHARM DRUG&MED:CLOPIDOGREL SANDOZ 75MG 2X14T(SAN-AUS)EACH FILM COA TAB CONT:CLOPID BISULFATE USP EQ TO CLOPIDO(ASPERINV)TBS | $326.1K | 12 |
| PHARMA DRUGS & MEDI CLOPIDOGREL 75MG 2X1 | $205.1K | 11 |
| PHARMA DRUGS & MEDI CLOPIDOGREL ACCORD 75MG 10X10T(ACOR-SWED AS PER INVOICE | $189.3K | 20 |
| PHARM DRUG&MED:CLOPIDOGREL SANDOZ 75MG 2X14T(SAN-AUS) EACH FILM COATED TABLET CONT:CLOPIDOGREL BISULFATE USP(ASPERINV) | $178.0K | 4 |
| PHARM DRUG&MED:CLOPIDOGREL SANDOZ 75MG 2X14T(SAN-AUS)EACH FILM COATED TABLET CONT CLOPIDOGREL BISULFATE USP EQ(ASPERINV) | $142.0K | 4 |
| PHARM DRUG&MED:CLOPIDOGREL SANDOZ 75MG 2X14T(SAN-AUS)EACH FILM COAT TABLET CONT:CLOPIDOGREL BISULFATE USP EQ TO(ASPERINV | $136.3K | 3 |
| PHARMA DRUGS & MEDI CLOPIDOGREL ACCORD 7 | $123.5K | 5 |
| PHARM DRUG&MED: CLOPIDOGREL SANDOZ 75MG | $100.0K | 2 |
Intas Pharmaceuticals Limited exports 131 distinct Clopidogrel formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHARMA DRUGS & MEDI CLOPIDOGREL TABLETS with 9 shipments worth $345.2K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Clopidogrel to Key Markets
What Intas Pharmaceuticals Limited must comply with to export Clopidogrel to its top destination countries
Australia — TGA
Approval Process
Registration on Australian Register of Therapeutic Goods (ARTG). Bioequivalence and quality data per TGA guidelines.
Timeline: 10–14 months
GMP & Export Requirements
TGA GMP clearance; PIC/S-aligned inspection. PIC/S certificate from India may expedite.
TGA sponsor licence for Australian importer; GMP clearance per manufacturing site
Note: TGA participates in PIC/S mutual recognition.
Brazil — ANVISA
Approval Process
Generic registration under RDC 200/2017. ANVISA GMP inspection of Indian facility mandatory before approval.
Timeline: 12–24 months
GMP & Export Requirements
ANVISA GMP certificate (CBPF) for each manufacturing site; on-site inspection by ANVISA
Certificate of Pharmaceutical Product from CDSCO; Import Authorization via SISCOMEX
Note: ANVISA maintains active Indian pharma facility inspection program. Inspection backlog can extend timelines.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Intas Pharmaceuticals Limited Compare to Nearest Clopidogrel Exporters?
Exporters ranked immediately above and below #14 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 11 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $7.5M | 150 | 13 | $50.0K |
| 8 | AJANTA PHARMA LIMITED | $7.0M | 140 | 18 | $50.0K |
| 14 | INTAS PHARMACEUTICALS LIMITED ★ | $5.3M | 301 | 19 | $17.6K |
| 9 | SANDOZ PRIVATE LIMITED | $5.3M | 105 | 7 | $50.0K |
| 15 | MICRO LABS LIMITED | $5.2M | 217 | 20 | $24.0K |
Intas Pharmaceuticals Limited ranks #14 among 416 Indian Clopidogrel exporters. Average shipment value of $17.6K compared to the market average of $320.2K. The closest competitors by value are SUN PHARMACEUTICAL INDUSTRIES LIMITED and AJANTA PHARMA LIMITED.
Which Indian Ports Ship Clopidogrel Exports?
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 576 | 9.5% |
| HYDERABAD ICD (INSNF6) | 490 | 8.1% |
| HYDERABAD ICD | 408 | 6.8% |
| SAHAR AIR CARGO ACC (INBOM4) | 366 | 6.1% |
| SAHAR AIR | 350 | 5.8% |
| JNPT/ NHAVA SHEVA SEA | 295 | 4.9% |
| DELHI AIR CARGO ACC (INDEL4) | 267 | 4.4% |
| DELHI AIR | 256 | 4.2% |
What Other Cardiovascular Products Does Intas Pharmaceuticals Limited Export?
Intas Pharmaceuticals Limited also exports these cardiovascular products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Intas Pharmaceuticals Limited's Clopidogrel Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Intas Pharmaceuticals. The Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and raised freight rates by 40–50% on key India–Europe routes, impacting the cost-effectiveness and timeliness of exports. (livemint.com)
Conversely, the ongoing US-China trade tensions have opened avenues for Indian pharmaceutical companies to capture a larger share of the U.S. market. Intas's acquisition of UDENYCA® and the FDA's acceptance of its biosimilar applications position the company to leverage these opportunities effectively. However, compliance with the European Union's Falsified Medicines Directive (FMD) remains a critical factor for market access. Intas's proactive approach in securing partnerships and ensuring regulatory compliance underscores its commitment to maintaining and expanding its presence in the European market.
Intas Pharmaceuticals Limited — Regulatory Compliance & Quality Standards
Maintaining stringent regulatory compliance is paramount for Indian pharmaceutical exporters. Intas Pharmaceuticals has demonstrated a strong commitment to adhering to international quality standards, as evidenced by its successful acquisitions and partnerships that necessitate compliance with FDA, WHO, and EU Good Manufacturing Practices (GMP). The company's proactive engagement in regulatory processes, such as the FDA's acceptance of its Biologics License Application for DMB-3115, reflects its dedication to quality and compliance. (intaspharma.com) As global regulatory requirements continue to evolve, Intas's focus on quality assurance and compliance positions it favorably in the competitive pharmaceutical export market.
About Intas Pharmaceuticals Limited
Intas Pharmaceuticals Limited exports 75 products worth $372.3M. Beyond Clopidogrel, top products include Ras, Mycophenolate, Tacrolimus, Apixaban, Ezetimibe. View the complete Intas Pharmaceuticals Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Clopidogrel — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Clopidogrel shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Intas Pharmaceuticals Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 303 individual customs records matching Intas Pharmaceuticals Limited exporting Clopidogrel, covering 131 formulations to 20 countries via 33 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 137+ countries, 1,234+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Clopidogrel Export Data from Intas Pharmaceuticals Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Intas Pharmaceuticals Limited's Clopidogrel exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Intas Pharmaceuticals Limited
Full Company Profile →
75 products · $372.3M total trade · 19 categories
Clopidogrel Stats
Company Overview
Top Products by Intas Pharmaceuticals Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Intas Pharmaceuticals Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Clopidogrel. For current shipment-level data, contact TransData Nexus.